Literature DB >> 32890272

Genetics of renovascular hypertension in children.

Daan H H M Viering1, Melanie M Y Chan2, Lieke Hoogenboom3, Daniela Iancu2, Jeroen H F de Baaij1, Kjell Tullus3, Robert Kleta3,2, Detlef Bockenhauer3,2.   

Abstract

OBJECTIVE: In most cases of renovascular hypertension in children, the cause is unclear. The aim of this study was to investigate genetic variation as a factor in the development of renovascular hypertension in children.
METHODS: In a cohort of 37 unrelated children from a single tertiary referral center, exome sequencing was performed. We assessed variants in recognized and suspected disease genes and searched for novel ones with a gene-based variant-burden analysis.
RESULTS: In the majority of patients, exome sequencing could not identify causative variants. We found a pathogenic variant in a recognized associated disease gene in five patients (three pathogenic variants in NF1, one in ELN and a deletion of chromosome 7q11.23, consistent with Williams syndrome). In two other patients, (likely) pathogenic variants were found in putative renovascular hypertension genes (SMAD6 and GLA), with clinical implications for both. Ten additional patients carried variants of uncertain significance (VUS) in known (n = 4) or putative (n = 6) renovascular hypertension disease genes. Rare variant burden analysis yielded no further candidate genes.
CONCLUSION: Genetic contributors, such as germline mutations in NF1, ELN, 7q11.23del were present in only 5 out of 37 (14%) children with renovascular hypertension. Twelve other children (32%) had potentially causal variants identified, including a pathogenic variant in SMAD6; a vasculopathy gene hitherto unknown to link with renovascular hypertension. Most importantly, our data show that exome sequencing can rarely identify the cause of renovascular hypertension in nonsyndromic children. We suggest that nongenetic factors or somatic genetic variation will play a more important role.

Entities:  

Mesh:

Year:  2020        PMID: 32890272     DOI: 10.1097/HJH.0000000000002491

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

1.  [Identification of traditional Chinese drugs containing active ingredients for treating myocardial infarction and analysis of their therapeutic mechanisms by network pharmacology and molecular docking].

Authors:  S Zhao; K Liu; J Duan; X Tao; W Li; Y Bai; P Wei; M Xi; H Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

Review 2.  Opportunities and challenges for the use of common controls in sequencing studies.

Authors:  Genevieve L Wojcik; Jessica Murphy; Jacob L Edelson; Christopher R Gignoux; Alexander G Ioannidis; Alisa Manning; Manuel A Rivas; Steven Buyske; Audrey E Hendricks
Journal:  Nat Rev Genet       Date:  2022-05-17       Impact factor: 59.581

3.  Analysis of 200,000 Exome-Sequenced UK Biobank Subjects Implicates Genes Involved in Increased and Decreased Risk of Hypertension.

Authors:  David Curtis
Journal:  Pulse (Basel)       Date:  2021-07-05

4.  Molecular genetic evaluation of pediatric renovascular hypertension due to renal artery stenosis and abdominal aortic coarctation in neurofibromatosis type 1.

Authors:  Dawn M Coleman; Yu Wang; Min-Lee Yang; Kristina L Hunker; Isabelle Birt; Ingrid L Bergin; Jun Z Li; James C Stanley; Santhi K Ganesh
Journal:  Hum Mol Genet       Date:  2022-02-03       Impact factor: 5.121

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.